Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: TATRADER who wrote (55535)	5/25/2006 10:10:23 AM
From: hotlinktuna	Respond to of 59879

Best of luck Mark! AVVW .05 HOD has news out now too: avVaa World Health Care Products Introduces Private Label Program Thursday May 25, 10:00 am ET LUMBY, British Columbia, May 25 /PRNewswire-FirstCall/ -- avVaa World Health Care Products, Inc. (OTC Bulletin Board: AVVW - News), a biotech company offering global customers therapeutic skin and health care products, announced today the launch of the Company's private label program for its human and pet skincare lines. ADVERTISEMENT For its primary line of quality human skin care products, avVaa is actively seeking collaboration with drug store chains and manufacturers to provide private labeling for its NeuroSkin(TM) mild skin moisturizer, NeuroSkin spray for eczema/psoriasis relief and its NeuroSkin acne treatment. avVaa's NeuroSkin line includes high quality products that aid in the treatment of a wide variety of conditions, including: eczema, psoriasis, dermatitis, acne and rosacea. avVaa is also actively negotiating private label partnerships for its acne, burn applications and various cosmetic lines. "Now that our high quality, therapeutic products will be actively distributed in U.S. and Canada, private labeling allows our products to benefit from immediate brand recognition and gain rapid market acceptance while providing avVaa immediate access to revenue building opportunities," said Jack Farley, CEO and chairman of avVaa World Health Care Products. "We look forward to growing our business and product lines while partnering with some of the best names in retail throughout Canada and the U.S." avVaa is currently negotiating with a pet care product manufacturer for a private label agreement for its pet and equine dermalustre(TM) products- therapeutic, all natural skin and coat treatment for animals. avVaa is also actively seeking partnerships with retail pet care chain stores to develop private label products that benefit from avVaa's proven formulas as well as the established brand recognition and loyalty of the U.S. and Canada's most popular retailers. For more information on private labeling opportunities with avVaa, please contact George Roadman, 508-282-1454. About avVaa World Health Care Products avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC NeuroSkin(TM) line of skin care products through mass, food and drug channels in the United States and globally. The Company's secondary line of equine and pet care related products are already being distributed throughout all of Canada and parts of the United States. For more information, visit: avvaa.com or otcfn.com. Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward- looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition. Contact: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349 or Rick McCaffrey at OTC Financial Network, Investor Relations, 781-444-6100 x625. Tracy Bagatelle-Black Mark Wachs & Associates 661/263-1842 tbagatelleblack@earthlink.net -------------------------------------------------------------------------------- Source: avVaa World Health Care Products, Inc.